Group Coordinator: Carla Cruz
Vice-coordinator: Diana Costa
Group description:
The Biopharmaceuticals and Biomaterials (BB) group is focused on the development of biopharmaceuticals, biomaterials for tissue engineering and regenerative applications, and nanomaterials for drug delivery, all to be applied in pharmaceutical and biomedical fields. Some examples are sustainable processes for the biosynthesis and purification of high-quality biopharmaceuticals (plasmids, minicircles, RNA, antibodies and polypeptides) for gene therapy and DNA vaccines; point-of-care biosensors for disease biomarkers detection; innovative nanomedicines to effectively deliver biopharmaceuticals/drugs for application in cancer therapy and infection; functionalised biomaterials for bone tissue and skin regeneration.
The group has collaborated to develop disruptive translational innovations to benefit human health, by converging fundamental research discoveries into applied research.
Keywords:
Nanotechnology, Biologics Bioprocessing, Health Biotechnology, Tissue Engineering
General objective:
to develop biopharmaceuticals, biomaterials for tissue engineering and regenerative applications, and nanomaterials for drug delivery, all to be applied in pharmaceutical and biomedical fields.
Specific objectives:
1. To develop sustainable processes for the biosynthesis and purification of high-quality biopharmaceuticals (plasmids, minicircles, and RNA) for gene therapy and DNA vaccines.
2. To develop point-of-care biosensors for disease biomarkers detection.
3. To develop innovative nanomedicines to effectively deliver biopharmaceuticals/drugs for application in cancer therapy and infection.
4. To produce and characterise functionalised biomaterials for bone tissue and skin regeneration.